Safety and Toxicity

The CDRI (Central Drug Research Institute) Lucknow, conducted the following studies in mice rats, rabbits, and rhesus monkeys.

  * acute toxicity
  * subacute and chronic toxicity
  * teratogenic and mutagenic


The results indicated that Gugulipid extract was safe for human consumption.

A four-week, phase 1 (safety on chronic administration) study was conducted on 21 subjects with the following conditions.

* 9 patients with Hypertension
* 3 patients with IHD
* 2 patients with Diabetes Mellitus
* 3 patients with Diabetes Mellitus & Hypertension
* 3 patients with IHD & Hypertension
* 1 patient with Gout

All subjects received 400 mg of Gugulipid three times a day (equivalent to 25 mg of guggulsterones). No adverse effects were reported for liver function, blood glucose, blood urea levels, hematological parameters, or electrocardiogram results. Only one patient complained of epigastric fullness three days after Gugulipidadministration that was controlled by antacids.

"These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, cure, or prevent any disease"

 

Copyright © Sabinsa Corporation. All Rights Reserved